Characterization of enriched CD34+ cells from healthy volunteers and those from patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF)

Stem Cells. 1995 May;13(3):273-80. doi: 10.1002/stem.5530130308.

Abstract

CD34+ cells were enriched, using a panning method, from peripheral blood (PB) and bone marrow (BM) of healthy volunteers and of patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF). In healthy volunteers, PB CD34+ cells expressed CD33 and CD13 at a higher frequency than BM CD34+ cells, and PB CD34+ cells contained a greater number of burst-forming units-erythroid (BFU-E) than colony-forming units granulocyte-macrophage (CFU-GM). Administration of G-CSF to healthy volunteers induced a marked increase in the number of PB CD34+ cells, although the proportions of those expressing CD33, CD13, and c-kit among these cells as well as colony-forming ability were not changed before and after G-CSF administration. There were no significant differences in surface antigens on PB CD34+ cells between healthy volunteers and patients after chemotherapy plus G-CSF, except for low expression of c-kit in the PB of patients. However, PB CD34+ cells from patients contained almost the same number of CFU-GM as BFU-E. These results indicate that there were clear differences in the features of CD34+ cells from BM and from PB, and between healthy volunteers and patients after chemotherapy plus G-CSF. Enriched CD34+ cells are useful for analyzing the characteristics of hematopoietic progenitor cells, and such analysis may predict the usefulness of autologous or allogeneic peripheral blood stem cell transplantation.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Antigens, CD / analysis*
  • Antigens, CD / blood
  • Antigens, CD34
  • Antigens, Differentiation, Myelomonocytic / analysis
  • Antigens, Differentiation, Myelomonocytic / blood
  • Bone Marrow Cells*
  • CD13 Antigens / analysis
  • CD13 Antigens / blood
  • Cell Separation
  • Colony-Forming Units Assay
  • Cytarabine / therapeutic use
  • Granulocyte Colony-Stimulating Factor / pharmacology*
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Hematopoietic Stem Cell Transplantation
  • Hematopoietic Stem Cells / cytology*
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / immunology
  • Humans
  • Leukemia / blood
  • Leukemia / drug therapy*
  • Lymphoma / blood
  • Lymphoma / drug therapy*
  • Proto-Oncogene Proteins / analysis
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-kit
  • Receptor Protein-Tyrosine Kinases / analysis
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Receptors, Colony-Stimulating Factor / analysis
  • Receptors, Colony-Stimulating Factor / metabolism
  • Sialic Acid Binding Ig-like Lectin 3

Substances

  • Antigens, CD
  • Antigens, CD34
  • Antigens, Differentiation, Myelomonocytic
  • CD33 protein, human
  • Proto-Oncogene Proteins
  • Receptors, Colony-Stimulating Factor
  • Sialic Acid Binding Ig-like Lectin 3
  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Proto-Oncogene Proteins c-kit
  • Receptor Protein-Tyrosine Kinases
  • CD13 Antigens